93 related articles for article (PubMed ID: 10090848)
1. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
2. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy.
Yu W; Kim J; Ossowski L
J Cell Biol; 1997 May; 137(3):767-77. PubMed ID: 9151680
[TBL] [Abstract][Full Text] [Related]
3. RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.
Kondraganti S; Gondi CS; McCutcheon I; Dinh DH; Gujrati M; Rao JS; Olivero WC
Int J Oncol; 2006 Jun; 28(6):1353-60. PubMed ID: 16685436
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.
Wang S; Jiang L; Han Y; Chew SH; Ohara Y; Akatsuka S; Weng L; Kawaguchi K; Fukui T; Sekido Y; Yokoi K; Toyokuni S
Oncotarget; 2016 Oct; 7(43):69565-69578. PubMed ID: 27602956
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.
Nijziel MR; Van Oerle R; Hellenbrand D; Van Pampus EC; Hillen HF; Hamulyák K
J Thromb Haemost; 2003 May; 1(5):982-6. PubMed ID: 12871365
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of calreticulin as a novel plasminogen receptor.
Bharadwaj AG; Okura GC; Woods JW; Allen EA; Miller VA; Kempster E; Hancock MA; Gujar S; Slibinskas R; Waisman DM
J Biol Chem; 2024 Jan; 300(1):105465. PubMed ID: 37979915
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha (Intron A) upregulates urokinase-type plasminogen activator receptor gene expression.
Wu S; Murrell GA; Wang Y
Cancer Immunol Immunother; 2002 Jul; 51(5):248-54. PubMed ID: 12070711
[TBL] [Abstract][Full Text] [Related]
8. Construction of antisense RNA expression plasmid for u-PAR and its transfection to highly invasive PC-3M cell subclones.
Liao G; Li Q; Feng Y; Deng Y; Li Z; Gong F; Ma D
J Huazhong Univ Sci Technolog Med Sci; 2003; 23(4):369-72. PubMed ID: 15015638
[TBL] [Abstract][Full Text] [Related]
9. The inhibitory effects of an antisense u-PAR vector on invasion of highly invasive human prostate carcinoma PC-3M cell subclones.
Liao G; Li Q; Feng Y; Deng Y; Li Z; Gong F; Ma D
J Huazhong Univ Sci Technolog Med Sci; 2003; 23(2):101-4. PubMed ID: 12973920
[TBL] [Abstract][Full Text] [Related]
10. ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway.
Bharadwaj AG; McLean ME; Dahn ML; Cahill HF; Wasson MD; Arun RP; Walker OL; Cruickshank BM; Fernando W; Venkatesh J; Barnes PJ; Bethune G; Knapp G; Helyer LK; Giacomantonio CA; Waisman DM; Marcato P
Mol Oncol; 2024 Jan; 18(1):91-112. PubMed ID: 37753740
[TBL] [Abstract][Full Text] [Related]
11. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
Meng S; Tripathy D; Shete S; Ashfaq R; Saboorian H; Haley B; Frenkel E; Euhus D; Leitch M; Osborne C; Clifford E; Perkins S; Beitsch P; Khan A; Morrison L; Herlyn D; Terstappen LW; Lane N; Wang J; Uhr J
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17361-5. PubMed ID: 17079488
[TBL] [Abstract][Full Text] [Related]
12. Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation.
Andronicos NM; Chen EI; Baik N; Bai H; Parmer CM; Kiosses WB; Kamps MP; Yates JR; Parmer RJ; Miles LA
Blood; 2010 Feb; 115(7):1319-30. PubMed ID: 19897580
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the invasive traits of breast cancers by CYP1B1 via regulation of p53 to promote uPAR expression.
Kwon YJ; Kwon TU; Shin S; Lee B; Lee H; Park H; Kim D; Moon A; Chun YJ
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166868. PubMed ID: 37661069
[TBL] [Abstract][Full Text] [Related]
14. SPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferation.
Liu X; Lan Y; Zhang D; Wang K; Wang Y; Hua ZC
Am J Cancer Res; 2014; 4(6):683-97. PubMed ID: 25520860
[TBL] [Abstract][Full Text] [Related]
15. Rational peptide design for targeting cancer cell invasion.
Gomari MM; Arab SS; Balalaie S; Ramezanpour S; Hosseini A; Dokholyan NV; Tarighi P
Proteins; 2024 Jan; 92(1):76-95. PubMed ID: 37646459
[TBL] [Abstract][Full Text] [Related]
16. Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.
Hao W; Friedman A
PLoS One; 2016; 11(4):e0153508. PubMed ID: 27078836
[TBL] [Abstract][Full Text] [Related]
17. uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.
Mahmood N; Arakelian A; Khan HA; Tanvir I; Mazar AP; Rabbani SA
Bone Res; 2020; 8():18. PubMed ID: 32337090
[TBL] [Abstract][Full Text] [Related]
18. A proteomics-based survey reveals thrombospondin-4 as a ligand regulated by the mannose receptor in the injured lung.
Nørregaard KS; Jürgensen HJ; Heltberg SS; Gårdsvoll H; Bugge TH; Schoof EM; Engelholm LH; Behrendt N
J Biol Chem; 2024 Apr; 300(5):107284. PubMed ID: 38614208
[TBL] [Abstract][Full Text] [Related]
19. Migration dynamics of ovarian epithelial cells on micro-fabricated image-based models of normal and malignant stroma.
Alkmin S; Brodziski R; Simon H; Hinton D; Goldsmith RH; Patankar M; Campagnola PJ
Acta Biomater; 2019 Dec; 100():92-104. PubMed ID: 31568876
[TBL] [Abstract][Full Text] [Related]
20. Ovarian Cancer Cell Adhesion/Migration Dynamics on Micro-Structured Laminin Gradients Fabricated by Multiphoton Excited Photochemistry.
He RY; Ajeti V; Chen SJ; Brewer MA; Campagnola PJ
Bioengineering (Basel); 2015 Jul; 2(3):139-159. PubMed ID: 28952475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
